Ibrutinib Combination Therapy Extremely Well Tolerated in Early Trial - 101931

Spotlight
Video

Ibrutinib Combination Therapy Extremely Well Tolerated in Early Trial

ASHReport has 256 videos Subscribe Here

Loading........
Description: Jennifer Brown, MD of Dana Farber, discusses a current and promising trial that combines ibrutinib with a standard chemo-immunotherapy combination: fludarabine, cyclophosphamide, rituximab (FCR), at the 58th ASH Annual Meeting in San Diego, CA.
Shared By : ASHReport
Posted on : 12/09/16
Added : 2 years ago